AceLink Therapeutics' novel GCS inhibitor to be included in breakthrough therapy
Posted: Sun Feb 16, 2025 6:21 am
On December 4, 2024, Antag Therapeutics " Antag " , a company co-invested by Via Biotech , announced the completion of an 80 million euro Series A financing round. Antag is a leading biopharmaceutical company focused on targeting the glucose-dependent insulinotropic peptide GIP receptor to develop novel obesity treatments. The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma, Pictet, Longview Ventures, and the Danish Export and Investment Fund EIFO.
The financing will be used to advance the clinical development of Antag's lead drug candidate AT-7687. The drug is a glucose-dependent insulin secretagogue receptor GIPR antagonist that is administered subcutaneously once a week. At the same time, the financing will also support the expansion of Antag's R&D pipeline for other monthly injection treatment options.
The first patient was successfully enrolled in the Phase 1ab sri lanka telegram data clinical trial of GTA182 of Pailong Biopharmaceuticals for the treatment of MTAP- deficient solid tumors
On November 19, 2024, Apeiron Therapeutics, a precision oncology drug research and development company co-invested and incubated by Via Biotech, announced that it had successfully enrolled the first patient in its GTA182 Phase 1ab study for MTAP-deficient advanced solid tumors.
The study is designed to evaluate the safety, efficacy and pharmacokinetic properties of GTA182 at multiple escalating doses in adult patients with advanced solid tumors with MTAP deletions, as monotherapy or in combination with standard of care.
On November 1, 2024, the CDE official website announced that the rare disease drug AL01211 capsules of AceLink Therapeutics referred to as " AceLink " , in which Via Biopharmaceuticals participated in the investment and incubation, are planned to be included in the breakthrough therapy, and the indication is Fabry disease.
The financing will be used to advance the clinical development of Antag's lead drug candidate AT-7687. The drug is a glucose-dependent insulin secretagogue receptor GIPR antagonist that is administered subcutaneously once a week. At the same time, the financing will also support the expansion of Antag's R&D pipeline for other monthly injection treatment options.
The first patient was successfully enrolled in the Phase 1ab sri lanka telegram data clinical trial of GTA182 of Pailong Biopharmaceuticals for the treatment of MTAP- deficient solid tumors
On November 19, 2024, Apeiron Therapeutics, a precision oncology drug research and development company co-invested and incubated by Via Biotech, announced that it had successfully enrolled the first patient in its GTA182 Phase 1ab study for MTAP-deficient advanced solid tumors.
The study is designed to evaluate the safety, efficacy and pharmacokinetic properties of GTA182 at multiple escalating doses in adult patients with advanced solid tumors with MTAP deletions, as monotherapy or in combination with standard of care.
On November 1, 2024, the CDE official website announced that the rare disease drug AL01211 capsules of AceLink Therapeutics referred to as " AceLink " , in which Via Biopharmaceuticals participated in the investment and incubation, are planned to be included in the breakthrough therapy, and the indication is Fabry disease.